TIMENTIN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Apr 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIMENTIN is an injectable small-molecule antibiotic combination product approved in 1985 by GSK. The drug treats bacterial infections via injection. Mechanism of action and specific indications are not specified in available data.
LOE Approaching
As LOE approaches, commercial teams face declining revenues and shrinking headcount; career mobility out of this franchise should be prioritized.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TIMENTIN offers minimal career trajectory; the product is in managed decline with no linked job openings. Professionals on this team should seek lateral moves into growth franchises or development pipelines within GSK to advance their careers.
Brand ManagerField Sales Representative
Worked on TIMENTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.